Biota records small year-end loss
Wednesday, 27 August, 2008
Biota Holdings [ASX: BTA] recorded a small loss for the financial year, thanks largely to the legal battle with GlaxoSmithKline (GSK).
The company lost $6.5 million after tax, a significant reduction in last year's profit of $20.2 million.
Among the company's expenses were litigation costs of $21.8 million accrued due to the legal battle.
Biota had taken GSK to court claiming it had failed to promote Biota's flu treatment Relenza properly.
The case was recently settled, with Biota accepting $20 million from GSK.
The Victorian Supreme the court ordered both companies to pay their own litigation costs.
Another reason for the loss was a nearly 50 percent decrease of Relenza royalties to $20.5 million.
Nevertheless, the company remains in a strong cash position, with $60.2 million in the bank.
The company also predicts that with the long-running court case settled it will earn around $12 million in profit in FY09.
The company's share price was unaffected by the announcement.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...